Launch of IDS-iSYS

Immunodiagnostic Systems Holdings plc.

10 August 2017

Launch of IDS-iSYS Free Testosterone assay - new assay in the IDS fertility portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has today launched the IDS-iSYS Free Testosterone assay in the European market. This is a fully automated CLIA assay for use with serum and plasma samples on the IDS-iSYS Automated System.

The launch of the IDS-iSYS Free Testosterone assay is the third product released as part of the emerging fertility (steroid hormones) portfolio.

The IDS-iSYS Free Testosterone assay quantitatively measures a patient's Free Testosterone level and offers clinicians an easy, non-invasive way to diagnose and treat disorders involving the male sex hormones (androgens). Measurement of free testosterone may provide additional information in patients whereby the measured total testosterone levels are low.

As the first fully automated solution, the IDS-iSYS Free Testosterone assay is a valuable addition to the developing IDS fertility portfolio; allowing laboratories to benefit from reduced time to first result for measurement of patient samples.

The global market for testosterone testing is valued at around $110 million per year.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Regis Duval, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson